Cagrilintide Dosage Chart: Once-Weekly Titration, Research Protocols, and Practical Considerations

If you’re following the latest developments in peptide based therapies for obesity management, you’ve likely encountered cagrilintide—a long acting amylin analog that’s generating significant attention in metabolic research. This article provides a detailed cagrilintide dosage chart based on published clinical trials through 2025, written from Peptides Unleashed’s educational perspective to help you understand how researchers are studying this compound.

Cagrilintide is not FDA approved as of 2025. All dosage information presented here derives from clinical research protocols, not treatment advice. As a synthetic amylin analogue, cagrilintide represents a distinct approach from GLP-1 agonists like semaglutide and tirzepatide, targeting complementary mechanisms for weight reduction and metabolic control.

The dosage chart that follows focuses on once weekly cagrilintide administered via subcutaneous injection, gradual dose escalation spanning approximately 16-20 weeks, and dose ranges tested in phase 1-3 trials. Our mission at Peptides Unleashed—led by Dr. Bradley Thomas—is evidence-based peptide education for health-conscious readers, without selling or prescribing peptides.

Quick Cagrilintide Dosage Chart (Once-Weekly Titration)

The following chart summarizes the standard titration schedule derived from published trial protocols for cagrilintide for weight management:

Standard Once-Weekly Titration Schedule:

• Week 1-4: 0.25 mg weekly cagrilintide

• Week 5-8: 0.5 mg weekly

• Week 9-12: 1.0 mg weekly

• Week 13-16: 1.7 mg weekly

• Week 17+ (maintenance): 2.4 mg weekly

Higher monotherapy doses up to 4.5 mg weekly have been explored in phase 2 trial designs, though most combination protocols with semaglutide cap the maximum dosage at 2.4 mg to manage overlapping side effect profiles.

Titration steps are spaced approximately 4 weeks apart to limit GI side effects including nausea, constipation, and diarrhea. This gradual titration approach allows the gastrointestinal system and central nervous system satiety pathways to adapt progressively.

Research protocols may adjust escalation faster or slower based on individual tolerability. Any dosing in humans must be directed by a qualified healthcare provider or ethics-approved research team—this chart serves educational purposes only.

What Is Cagrilintide? Mechanism and Trial Context

Cagrilintide (designated AM833 in early development) is a synthetic amylin analogue and dual amylin/calcitonin receptor agonist developed by Novo Nordisk for obesity and type 2 diabetes research. Unlike pure GLP-1 receptor agonists, this important neuroendocrine hormone analogue targets distinct pathways that enhance appetite suppression through multiple physiological mechanisms.

The compound slows gastric emptying, promotes satiety through central nervous system signaling in the area postrema and hypothalamus, and inhibits postprandial glucagon secretion from pancreatic alpha cells. These actions complement GLP-1 signaling rather than duplicating it, creating potential for combination therapy approaches.

Key data emerged from a phase 2 trial published in The Lancet Diabetes Endocrinol in December 2021—a multicentre randomised double blind study testing once-weekly doses from 0.3 to 4.5 mg over 26 weeks in adults with BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities.

As of 2025, cagrilintide is being evaluated in large phase 3 programs (REDEFINE and REIMAGINE), often in fixed-dose combinations with semaglutide called “CagriSema” for weight loss and cardiometabolic outcomes. The compound is not commercially available—any online access involves research-only materials carrying legal and safety considerations.

Therapeutic Uses of Cagrilintide

Cagrilintide stands out as a promising long-acting amylin analog with a range of therapeutic uses that extend beyond simple weight loss. Its primary benefit lies in supporting effective weight management by promoting significant reductions in body weight. This is achieved through a dual mechanism: cagrilintide slows gastric emptying and enhances appetite control, leading to a natural decrease in food intake and sustained appetite suppression. These effects not only contribute to enhanced weight loss but also help individuals maintain their progress over time.

Beyond its impact on body weight, cagrilintide has demonstrated meaningful improvements in metabolic health. Clinical trials have shown that it can support better blood sugar control and glucose regulation, making it a potential tool for managing type 2 diabetes and related metabolic conditions. By targeting both appetite and blood sugar, cagrilintide addresses key aspects of metabolic control that are often challenging in obesity management.

One of the most exciting developments is the use of cagrilintide in combination therapy, particularly alongside semaglutide. This pairing leverages complementary mechanisms—while cagrilintide promotes satiety and slows gastric emptying, semaglutide enhances insulin secretion and further suppresses appetite. Together, they deliver enhanced weight loss and improved metabolic outcomes compared to either agent alone, offering significant benefits for those seeking comprehensive weight management solutions.

As research continues, cagrilintide’s role in appetite suppression, blood sugar regulation, and combination therapy positions it as a potential cornerstone in the future of obesity and metabolic health treatment.

Cagrilintide Dosage Chart: Escalation Phases and Ranges

Understanding the cagrilintide dosage chart requires breaking titration into distinct phases: initiation, mid-range therapeutic dosing, full maintenance dose, and high-dose monotherapy exploration.

Typical once-weekly escalation used in weight-loss research starts at 0.25-0.3 mg, then increases stepwise to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg over approximately 16-17 weeks. Some phase 2 studies tested higher doses up to 4.5 mg weekly to map the upper end of the dose-response curve and characterize the side-effect profile at maximum dose levels.

All chart numbers derive from published or publicly registered trial protocols (including NCT03856047 and subsequent REDEFINE/REIMAGINE programs), not from commercial weight loss clinics or unregulated sources.

Low-Dose Initiation Phase (0.25-0.6 mg Weekly)

This phase spans Weeks 1-4 (or longer if needed) and focuses on tolerance assessment and GI side-effect screening. The 0.25-0.3 mg once weekly starting point extrapolates from the dose-finding phase 2 trial, where the 0.3 mg arm showed:

• Early weight change of approximately 2-4% from baseline weight

• Nausea in only 20-30% of participants

• Reduced hunger scores by 20-30% on visual analog scales

Some protocols reference 0.3-0.6 mg weekly during early use to minimize nausea and allow the brain-gut axis to adapt to amplified satiety signals. This phase is where most participants first notice reduced food intake and smaller meal sizes.

In research settings, gradual dose escalation is typically delayed if participants report persistent moderate or severe GI symptoms lasting more than 7-14 days.

Moderate Dose Phase (1.0-2.4 mg Weekly)

This represents the therapeutic window for most weight-loss protocols, typically spanning Weeks 5-17 in clinical trials. At 1.0 mg weekly, appetite control becomes clearly noticeable and weekly weight reduction tends to accelerate.

The 1.7-2.4 mg weekly range serves as the most common maintenance target in phase 3 combination protocols pairing cagrilintide and semaglutide for obesity and type 2 diabetes populations.

Step Ladder Progression:

• 1.0 mg weekly (Weeks 9-12)

• 1.7 mg weekly (Weeks 13-16)

• 2.4 mg weekly (Week 17+ maintenance)

Dose increases within this range are spaced at 4-week intervals, provided GI symptoms remain mild or are resolving. Phase 2 data showed 8-9% total weight loss by week 26 at these moderate doses, with 60-70% of initial GI symptoms resolving at steady state.

High-Dose Monotherapy Phase (Up to 4.5 mg Weekly)

Once-weekly doses up to 4.5 mg have been studied as cagrilintide monotherapy in non-diabetic adults with obesity over 26 weeks. This controlled dose finding phase mapped the upper therapeutic ceiling.

At the 4.5 mg weekly maximum dosage:

• Phase 2 data showed 10.8% average weight loss (versus 2.5% placebo)

• 88% of participants reported at least one adverse event

• Nausea incidence reached 70-80%

• Vomiting occurred in 30-40% of participants

These higher doses are generally not used when cagrilintide is combined with full-dose GLP-1 agonists due to overlapping emetic pathways. High-dose regimens should remain within formal trial settings until long-term safety data from ongoing research provides clearer guidance.

Cagrilintide Dosage in Key Research Settings

Cagrilintide dosing varies depending on whether it’s used alone or with GLP-1 agonists, and whether primary outcomes target weight loss, glycemic control, or cardiovascular risk reduction. The following sections reference specific trial designs while keeping information concise and accessible.

These represent research protocols, not templates for at-home use. All dosing should be contextualized within trial names, endpoints, and supervised clinical settings.

Dosage in Weight-Loss Trials (Non-Diabetic Obesity)

The classic placebo controlled and active controlled dose finding phase 2 trial enrolled overweight and obese adults for 26-week treatment plus 6-week follow-up, testing administered once weekly cagrilintide from 0.3 to 4.5 mg.

Trial Design Summary:

• Participants started low and escalated every 4 weeks

• Target doses: 1.2, 2.4, or 4.5 mg weekly

• Results: 6-11% body weight reduction across treatment groups

• Higher doses achieved more weight loss but increased GI serious adverse events

Weekly cagrilintide for weight loss performed favorably compared to once-daily liraglutide 3.0 mg, with superior convenience through weekly rather than daily subcutaneous injection administration.

Dosage in Type 2 Diabetes and CagriSema Combination Trials

Cagrilintide semaglutide combinations are being studied for type 2 diabetes patients, with doses often converging on 2.4 mg cagrilintide plus 2.4 mg semaglutide once weekly after a 16-week escalation.

A representative 32-week randomised double blind placebo controlled phase 2 trial in 90+ adults with type 2 diabetes compared:

• Semaglutide monotherapy

• Cagrilintide monotherapy

• Combination with semaglutide

Dual-Escalation Pattern:

• Cagrilintide: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg

• Semaglutide: parallel or staggered escalation to 2.4 mg

Primary outcomes included HbA1c change (1.9% reduction in combination arms) and enhanced weight loss (15.6% at 20 weeks), with combination therapy outperforming monotherapy for both blood sugar control and weight management endpoints.

Dosage in Long-Term Cardiometabolic Outcome Studies

The REDEFINE phase 3 program (including REDEFINE-3) studies thousands of overweight and obese adults with and without type 2 diabetes over multiple years—representing potential future obesity treatment paradigms.

Long-Term Protocol Features:

• Standard 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly titration for cagrilintide

• Paired with stepwise semaglutide dosing

• Post-escalation maintenance at 2.4 mg weekly

• Duration: up to 4-4.5 years

• Endpoints: MACE (major adverse cardiovascular events), sustained weight trajectories

After the 16-week escalation, participants remain at maintenance dose while investigators track adherence, long-term tolerability, stable blood glucose levels, and cardiovascular outcomes.

Combining Cagrilintide with GLP-1 Agonists: Dosage Synergy

Cagrilintide is frequently combined with GLP-1 agonists because of complementary mechanisms—amylin pathways target gastric and vagal satiety signals while GLP-1 pathways address incretin effects and glucagon secretion inhibition from pancreatic beta cells.

CagriSema trials typically pair 2.4 mg cagrilintide with 2.4 mg semaglutide once weekly after gradual titration. Combination dosing uses lower cagrilintide maxima (2.4 mg) than some monotherapy trials (4.5 mg) due to additive GI effects.

Clinical trial data suggest greater than 20% average weight loss in some CagriSema cohorts—significant benefits exceeding results seen with either drug alone at similar doses. This represents one of the most promising approaches to treating obesity through peptide-based combination strategies.

Example Combination Titration Schedule (CagriSema-Style)

Week-by-Week Dual Titration:

• Weeks 1-4: 0.25 mg semaglutide + 0.25 mg cagrilintide

• Weeks 5-8: 0.5 mg + 0.5 mg

• Weeks 9-12: 1.0 mg + 1.0 mg

• Weeks 13-16: 1.7 mg cagrilintide + 1.0-2.4 mg semaglutide (staggered for GI sparing)

• Week 17+: 2.4 mg + 2.4 mg (maintenance)

Both injections are given subcutaneously once weekly on the same day, but in separate syringes at different injection sites at least 2-3 centimeters apart. Concomitant administration requires careful site rotation.

Titration speed adjusts based on tolerance—persistent moderate nausea or vomiting may trigger a hold or dose step-down. While tirzepatide combinations are less documented, similar principles of starting low and layering multiple doses would apply in future research.

None of these combinations are FDA approved regimens outside clinical trials. Dosage decisions must be overseen by investigators or prescribing physicians.

Safety, Side Effects, and Dose Adjustments

Cagrilintide’s side-effect profile broadly mirrors GLP-1 drugs: mostly GI issues that are dose-dependent and usually transient with slower escalation. The dosage chart is designed to reduce adverse events by moving in small increments (approximately 0.25-0.7 mg) and allowing several weeks at each level.

Frequently Reported Side Effects by Dose:

• Nausea: 40% (low dose) to 80% (high dose)

• Vomiting: 10-40%

• Constipation/diarrhea: 20-50%

• Abdominal discomfort: dose-dependent

• Injection site reactions: 5-15%

Important safety considerations include potential gallbladder issues (2-4% incidence, similar to GLP-1 class), pancreatitis signals monitored via amylase/lipase, and anti-cagrilintide antibodies reported in 50%+ of subjects—typically without loss of efficacy. Individuals with personal or family history of medullary thyroid carcinoma should discuss risks with their healthcare provider.

Clinical monitoring should include weekly weight tracking, symptom logs, quarterly HbA1c and labs for diabetic patients, and assessment of blood glucose levels and glucose regulation parameters.

Practical Tips for Tolerating Each Dose Step

Lifestyle strategies can accompany each escalation to support metabolic health and minimize discomfort:

Dietary Adjustments:

• Smaller, more frequent meals

• Slower eating pace

• Prioritize protein intake (may reduce nausea 30-50%)

• Avoid large, high-fat meals that aggravate delayed gastric emptying

Managing GI Symptoms:

• Maintain adequate hydration

• Increase fiber intake for constipation (especially at ≥1.7 mg weekly)

• Consider pausing titration if more than mild nausea persists beyond 1-2 weeks

• OTC ginger or simple antiemetics may help—consult your healthcare provider first

Injection Technique:

• Rotate injection sites (abdomen, thigh, upper arm)

• Sites should be several centimeters apart when combining multiple weekly peptides

• Proper technique reduces local reactions and supports lean mass preservation during weight loss

Treatment Access: Availability, Insurance, and Prescribing Considerations

As of 2025, cagrilintide remains an investigational therapy, available exclusively for research purposes and not yet FDA approved for clinical use. This means that individuals interested in cagrilintide for weight management or metabolic health must access it through participation in clinical trials or via research-grade suppliers, rather than through standard prescriptions.

Because cagrilintide is not yet an approved medication, insurance coverage is generally unavailable. Most participants in research settings or early access programs should expect to pay out-of-pocket for any associated costs. This underscores the importance of understanding the regulatory landscape and the limitations of insurance reimbursement until cagrilintide receives formal approval.

Prescribing considerations are critical for safety. Healthcare providers must thoroughly review each patient’s medical history, with particular attention to any personal or family history of medullary thyroid carcinoma, as this is a known risk factor that may preclude use. A careful, individualized treatment plan is essential, typically involving gradual dose escalation to minimize adverse events and optimize outcomes. Regular monitoring for serious adverse events, such as gastrointestinal symptoms or rare complications, is a key part of responsible cagrilintide administration.

Ongoing clinical trials—including the REDEFINE and REIMAGINE studies—are actively evaluating the safety, efficacy, and optimal dosing of cagrilintide for weight management and metabolic health. These studies are also helping to define the maximum dosage, with research protocols testing up to 4.5 mg administered once weekly via subcutaneous injection.

Looking ahead, cagrilintide holds promise as a future obesity treatment, potentially offering a new avenue for those seeking effective, science-backed weight management solutions. Until FDA approval is granted, access will remain limited to research settings, and all use should be guided by qualified healthcare professionals within the context of a structured treatment plan.

How to Use This Cagrilintide Dosage Chart Safely

This chart summarizes what researchers and clinicians have tested in formal trials—it does not constitute a treatment plan for individual implementation. The distinction between research-grade peptide dosing and prescription-grade, regulatory-approved medication dosing is critical.

If you’re interested in cagrilintide-like effects for glucose control or appetite suppression, discuss FDA approved options (such as GLP-1 agonists) with your physician while following ongoing research into innovative treatments publicly reported through trial registries.

This chart can help you:

• Better understand news about phase 3 results

• Read clinical trial registries more effectively

• Evaluate claims made by peptide vendors critically

For deeper guides on dosing philosophy, stacking strategies, and safety fundamentals, download Peptides Unleashed’s free peptide e-book and join our newsletter.

Evidence Summary and Future Directions for Cagrilintide Dosing

Once-weekly cagrilintide doses escalated from approximately 0.25-0.3 mg up to 2.4-4.5 mg over several months have produced 6-11% weight loss as monotherapy in double blind clinical trials. Combination with semaglutide achieves even greater results—17-20%+ weight reduction in some cohorts, with improved blood sugar and glucose levels.

Ongoing research through REDEFINE and REIMAGINE phase 3 programs will refine the optimal long-term dose (likely around 2.4 mg weekly) for both obesity and type 2 diabetes populations. These active controlled trials will generate the dose-response and tolerability data needed to shape future clinical guidelines if regulators approve cagrilintide-based therapies.

Maintain a critical, evidence-based lens when encountering online dosage calculators or aggressive marketing for research-use peptides. The extended half life and once-weekly convenience of this pancreatic hormone analogue represent genuine advances, but safety considerations require formal clinical oversight.

At Peptides Unleashed, we provide unbiased, physician-informed education so you can have more informed conversations with your healthcare provider about peptide-based strategies. Understanding cagrilintide dosing through published research empowers you to follow developments in this rapidly evolving field—whether you’re tracking Lancet Diabetes Endocrinol publications or evaluating claims about the next breakthrough in obesity management.